Genetic drivers of cancer growth and resistance mechanisms

Tue2  Sep02:05pm(55 mins)
Charter 1
Plenary Keynote:
Dr Susan Galbraith


Recent approvals for oncology drugs have seen an increasing proportion directed to specific genetic targets i with a companion diagnostic test. This presentation compares and contrasts the discovery and development of gefitinib - the first EGFR tyrosine kinase inhibitor and AZD9291, an irreversible inhibitor of both sensitizing and resistant mutated EGFR. This demonstrates how the better understanding we now have of the genetic changes driving the cancer growth and the biochemical structure and function of the mutated proteins, has lead to a much faster developmental path with higher likelihood of success in pivotal trials. I will also discuss the emerging trend of the development of ‘basket’ studies which include one or more screening tests for multiple genetic aberrations and the direction of patients to one of several arms of a clinical trial based on the specific aberration in their tumour.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021